Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Platinum-resistant Ovarian Cancer 1Metastatic Castration-resistant Prostate Cancer 1Hematologic Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

enzalutamide 2radium Ra 223 dichloride 1poly ICLC 1olaparib 1fluciclovine F-18 1cabazitaxel 1bempegaldesleukin 1afuresertib 1Radiosurgery 1Radionuclide Imaging 1Prednisone 1Nivolumab 1Docetaxel 1Clinical Trials, Phase I as Topic 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Metastatic Castration-resistant Prostate Cancer × afuresertib × Clear all
NCT04060394 2024-10-10

Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC

Laekna Limited

Phase 1/2 Completed
49 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡